Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

The trial results demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior ... 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent ...

The TAVR market, which has been a key driver of Edwards Lifesciences' growth in recent years, is facing a period of moderation. The company has reported a slowdown in TAVR sales, attributing this ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...

Edwards Lifesciences’ EW fourth ... TAVR sales growth was supported by the continued launch of SAPIEN 3 Ultra RESILIA in Europe. Management anticipates TAVR growth momentum to continue as ...